Bosutinib is a potent tyrosine kinase inhibitor (TKI) active at nM concentration on BCR-ABL1
and most BCR-ABL1 mutations. Bosutinib has been approved by the FDA and the EMA for the
treatment of patients with Ph+/BCR-ABL1+ chronic myeloid leukemia who fail treatment with
other TKIs, first or second line. The goal of second-line treatment of CML is to achieve a
response that would predict for a survival equal to, or very close to, the survival of non
leukemic people, that is to say to achieve a complete cytogenetic response (CCyR) or a major
molecular response (MMR). To achieve that goal, it is necessary to find and keep the right
balance between activity, safety, and tolerability. There are no studies comparing TKIs in
second-line. From phase 2, single-arm, studies, the reported efficacy of Bosutinib is similar
to the reported efficacy of dasatinib and nilotinib. The median age of newly diagnosed CML
patients is about 56 years, and at least 40% of all newly diagnosed patients are more than 60
years old. Particularly for these patients, the choice of the TKI must take into account the
safety and the tolerability profile of the TKIs. The use of dasatinib and nilotinib is
burdened by pleural and pulmonary complications, by infections, and by cardiovascular,
thrombotic and metabolic (diabetes mellitus, dyslipidemia) complications. These complications
are more frequent and more clinically relevant in the elderly. The safety and tolerability of
Bosutinib has been reported in first- as well as in second- and third-line. The standard dose
(500 mg once daily) is tolerated and safe, but at that dose several adverse events (AEs)
limit the tolerability, require dose reduction or interruption, and affect patient quality of
life, including diarrhea, nausea, vomiting, skin rash. Also an increase of AST, ALT and
lipase are of concern and a cause of treatment discontinuation. On the contrary, an increased
frequency of infections and of pleuro-pulmonary, cardiovascular, thrombotic, and metabolic
AEs has not been reported. The reported hematologic toxicity of Bosutinib is at least as low
as, or even lower than, that reported for the other TKIs, in spite of the fact that Bosutinib
is a dual, BCR-ABL1 and src inhibitor. Until today, all studies of TKIs in CML have tested a
fixed initial dose, providing for dose adjustment in case of toxicity (dose decrease) or in
case of unsatisfactory response (dose increase). No study so far was designed to test the
adaptation of the dose to the response, taking advantage of the fact that the efficacy of TKI
treatment can be assessed rapidly and precisely by measuring the BCR-ABL1 transcripts level
with real-time PCR (RT-PCR) in peripheral blood cells. An RT-PCR monthly for the first few
months provides the best assessment of the response to treatment. We predict that a more
flexible strategy of treatment (adapting the dose to the response) will result into a more
convenient balance between activity and toxicity, hence into a better outcome. Based on these
premises, it is proposed to test the activity, the safety, and the tolerability of Bosutinib,
second-line, beginning with a low dose and adjusting subsequent doses based on molecular
response, and on AEs, in a population of elderly patients. In almost all prior studies of
TKIs in second- or third-line, the primary efficacy was assessed using cytogenetic response,
both major and complete, at different time points. To make the results of this study
comparable to the results of prior studies, the cytogenetic response will be evaluated as
specified in section 5, but since the response to therapy and the evaluation of the efficacy
of therapy are more and more based on molecular response, dose adaptation and efficacy
evaluation will be based primarily on molecular response.
Inclusion Criteria:
1. Molecular confirmed diagnosis of BCR-ABL1+ CML
2. Chronic phase CML (ELN 2013 criteria)
3. 60 years of age or older
4. Prior first-line treatment with any other TKIs
5. Intolerance to prior treatment, based on investigator and patient assessment or
failure of prior treatment according to any one of the ELN 2013 criteria, as listed
below
- Non complete hematologic response (CHR) at 3 months
- No cytogenetic response (Ph+ > 95%) at 6 months
- Less than Partial Cytogenetic Response (PCyR) (Ph+ >35%) at 6 months
- BCR-ABL1 > 10% at 6 months
- Non complete CyR (CCyR) (Ph+ > 0) at 12 months
- BCR-ABL1 > 1% at 12 months
- Loss of CHR at any time
- Loss of CCyR at any time
- Confirmed loss of major molecular response (MMR) (BCR-ABL1 > 0.1%) in two
consecutive tests, of which one > 1%, at any time
6. An effective form of contraception from enrolment through 30 days after the end of
treatment
7. Signed written informed consent according to ICH/EU/GCP and national and local laws
prior to any study procedures
8. Willingness and ability to comply with scheduled visits and study procedures.
Exclusion Criteria:
1. Accelerated or blastic phase CML (according to ELN 2013 criteria)
2. Patients with the T315I or the V299L mutation
3. Patients previously treated with 2 TKIs or more
4. Compelled to take medications that are known to be associated with Torsades de Pointes
and/or with significant QTc prolongation
5. Any condition or illness that, in the opinion of the Investigator, would compromise
patient safety or interfere with the evaluation of the drug
6. HBV markers positivity
7. Lack of informed consent
